Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Soft Tissue Sarcoma
NCT00330421Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in soft tissue sarcoma (STS), Ewing sarcoma, osteosarcoma (OS) and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax), Change in Interstitial Fluid Pressure (IFP) and 5 more. Started Jun 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
soft tissue sarcoma (STS)Ewing sarcomaosteosarcoma (OS)Peripheral Primitive Neuroectodermal Tumor (pPNET)
Beyond the preview
Go deeper on NCT00330421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330421.